High PD-L1 TPS (50 percent or more)
A high PD-L1 score in lung cancer that opens discussion of immunotherapy without chemotherapy.
Parent marker: PD-L1
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Clinical meaning
In this group immunotherapy alone is often discussed as a first-line option. The decision still takes into account the history of autoimmune disease and the patient's condition.
How this finding appears in a report
The TPS score is derived from platform-specific immunohistochemistry; numbers from different platforms cannot be directly compared.
When therapy stops working
Progression after immunotherapy may prompt tissue reexamination and consideration of clinical trials.
What needs verification
- Complete variant name as written in the laboratory report.
- Examination methods and types of samples used.
- Examination dates were compared with ongoing therapy.
Marker context: PD-L1
PD-L1 scores are reported to differ according to cancer type: TPS (tumor proportion score) in lung cancer, CPS (combined positive score) in gastric cancer. Rates from one type of cancer cannot be transferred to another type of cancer.
A negative result does not always mean absent
Summary
- Gen
- CD274
- Variant
- PD-L1 TPS 50 persen atau lebih
- Alteration type
- Scale status
- Discussed in
- Lung Cancer
- Updated
- 2026-09-10
Other names in reports
TPS >= 50, PD-L1 high
Drugs discussed
Treatment categories
Related guides
Sources
- NCI Dictionary of Cancer Terms(lembaga)
- ClinicalTrials.gov(registry)
Clinical trials
Studies mentioning marker PD-L1
Filtered from public study descriptions. Access status and site readiness remain unverified.
NCT06170788Phase 3Immunotherapy
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Lung Cancer | biomarker: PD-L1 | Immunotherapy, Perawatan suportif dan paliatif
United States, Argentina, Australia +23220 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker PD-L1, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06170788Not verified
NCT06203600Phase 2 / Phase 3Combination regimen
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Stomach Cancer | biomarker: PD-L1 | Immunotherapy, Targeted therapy, Chemotherapy
United States375 registry sites
Why this appears: Appears because it is recorded for Stomach Cancer, it mentions marker PD-L1, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06203600Not verified
NCT05920356Phase 3Combination regimen
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Lung Cancer | biomarker: KRAS, PD-L1 | Immunotherapy, Targeted therapy, Chemotherapy
United States, Argentina, Australia +35421 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker KRAS, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT05920356Not verified
NCT06119581Phase 3Immunotherapy
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Lung Cancer | biomarker: KRAS, PD-L1 | Immunotherapy, Chemotherapy
United States, Australia, Austria +26415 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker KRAS, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06119581Not verified
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- PD-L1
Biomarker
Reason: Related through a biomarker
- Lung Cancer
Cancer type
Reason: Related to this page
- Atezolizumab
Drug
Reason: Related to this page
- Cemiplimab
Drug
Reason: Related to this page
- Immunotherapy
Treatment category
Reason: Related to this page
- Pembrolizumab
Drug
Reason: Related to this page
To check
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.